AbbVie annual debt-to-equity ratio
2013
2014
2015
2016
2017
2020
2021
2022
2023
2024
AbbVie Debt-to-Equity Ratio Growth & History (ABBV)
AbbVie's debt-to-equity ratio was 20.46 for fiscal 2024.
View full AbbVie company overviewAbbVie annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 20.46 | 14.64 | +251.55% |
| 2023 | 2023-12-31 | 5.82 | 2.10 | +56.42% |
| 2022 | 2022-12-31 | 3.72 | −1.31 | −26.09% |
| 2021 | 2021-12-31 | 5.03 | −1.62 | −24.37% |
| 2020 | 2020-12-31 | 6.66 | — | — |
| 2017 | 2017-12-31 | 7.25 | −0.61 | −7.79% |
| 2016 | 2016-12-31 | 7.87 | −0.06 | −0.75% |
| 2015 | 2015-12-31 | 7.93 | −0.43 | −5.13% |
| 2014 | 2014-12-31 | 8.35 | 5.17 | +162.23% |
| 2013 | 2013-12-31 | 3.19 | — | — |
AbbVie quarterly debt-to-equity ratio
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2025 | 2025-03-31 | 46.56 | 38.59 | +484.30% |
| Q4 2024 | 2024-12-31 | 20.46 | 14.64 | +251.55% |
| Q3 2024 | 2024-09-30 | 9.70 | 5.10 | +110.86% |
| Q2 2024 | 2024-06-30 | 8.56 | 4.23 | +97.42% |
| Q1 2024 | 2024-03-31 | 7.97 | 3.50 | +78.40% |
| Q4 2023 | 2023-12-31 | 5.82 | 2.10 | +56.42% |
| Q3 2023 | 2023-09-30 | 4.60 | 0.82 | +21.79% |
| Q2 2023 | 2023-06-30 | 4.34 | 0.17 | +4.17% |
| Q1 2023 | 2023-03-31 | 4.47 | 0.56 | +14.48% |
| Q4 2022 | 2022-12-31 | 3.72 | −1.31 | −26.09% |
| Q3 2022 | 2022-09-30 | 3.78 | −1.69 | −30.90% |
| Q2 2022 | 2022-06-30 | 4.16 | −1.74 | −29.51% |
| Q1 2022 | 2022-03-31 | 3.90 | −1.51 | −27.90% |
| Q4 2021 | 2021-12-31 | 5.03 | −1.62 | −24.37% |
| Q3 2021 | 2021-09-30 | 5.47 | 0.07 | +1.37% |
| Q2 2021 | 2021-06-30 | 5.91 | 0.32 | +5.80% |
| Q1 2021 | 2021-03-31 | 5.41 | — | — |
| Q4 2020 | 2020-12-31 | 6.66 | — | — |
| Q3 2020 | 2020-09-30 | 5.39 | — | — |
| Q2 2020 | 2020-06-30 | 5.58 | — | — |
| Q1 2018 | 2018-03-31 | 8.80 | 1.41 | +19.13% |
| Q4 2017 | 2017-12-31 | 7.25 | −0.61 | −7.79% |
| Q3 2017 | 2017-09-30 | 5.20 | −0.56 | −9.77% |
| Q2 2017 | 2017-06-30 | 5.69 | −1.01 | −15.09% |
| Q1 2017 | 2017-03-31 | 7.39 | 0.95 | +14.76% |
| Q4 2016 | 2016-12-31 | 7.87 | −0.06 | −0.75% |
| Q3 2016 | 2016-09-30 | 5.76 | −0.84 | −12.74% |
| Q2 2016 | 2016-06-30 | 6.71 | 1.78 | +36.12% |
| Q1 2016 | 2016-03-31 | 6.44 | −1.73 | −21.22% |
| Q4 2015 | 2015-12-31 | 7.93 | −0.43 | −5.13% |
| Q3 2015 | 2015-09-30 | 6.60 | 3.43 | +107.71% |
| Q2 2015 | 2015-06-30 | 4.93 | 2.11 | +74.63% |
| Q1 2015 | 2015-03-31 | 8.17 | 5.11 | +166.76% |
| Q4 2014 | 2014-12-31 | 8.35 | 5.17 | +162.23% |
| Q3 2014 | 2014-09-30 | 3.18 | −0.95 | −23.08% |
| Q2 2014 | 2014-06-30 | 2.82 | −1.32 | −31.88% |
| Q1 2014 | 2014-03-31 | 3.06 | −1.88 | −38.06% |
| Q4 2013 | 2013-12-31 | 3.19 | — | — |
| Q3 2013 | 2013-09-30 | 4.13 | — | — |
| Q2 2013 | 2013-06-30 | 4.14 | — | — |
| Q1 2013 | 2013-03-31 | 4.95 | — | — |
AbbVie debt-to-equity ratio trends
Between the periods ended 2013-12-31 and 2024-12-31, AbbVie's debt-to-equity ratio increased from 3.19 to 20.46, a change of 17.27. The latest reported quarter, Q1 2025, shows 46.56.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...